

REMARKS

Claims 1 – 37 were submitted with the original specification of this application. Applicants have hereinabove canceled claims 10-18 and 23-37 without prejudice to applicants' right to pursue the subject matter of the canceled claims in one or more divisional or continuation applications, and have amended claims 1-9 and 19-22 and added new claims 38-56. Accordingly, upon entry of this amendment, claims 1-9, 19-22 and 38-56 are pending.

Applicants maintain that the amendment of claims 1-9 and 19-22, and the addition of new claims 38-56 raises no issue of new matter. All of the amendments and additions are made to conform the claims to U.S. practice and to reduce the number of independent claims so as to reduce excess claims fees. Claims 23 to 37 have been replaced with new claims 38-56, with the correspondence indicated below:


- New claim 38 corresponds to original claim 24;
- New claims 39, 41, 43, 50, 52 and 54 correspond to original claim 31;
- New claim 40 corresponds to original claim 23;
- New claim 42 corresponds to original claim 25;
- New claim 44 corresponds to original claim 33;
- New claim 45 corresponds to original claim 27;
- New claim 46 corresponds to original claim 32;
- New claim 47 corresponds to original claim 26;
- New claim 48 is new, and was added to properly claim a preferred embodiment of the invention of original claim 26;
- New claim 49 corresponds to original claim 28;
- New claim 51 corresponds to original claim 29;
- New claim 53 corresponds to original claim 30;
- New claim 55 corresponds to original claims 34, 35 and 36; and
- New claim 56 corresponds to original claim 37.

Applicants submit that the differences between the new claims and the original claims merely reflect rewording of the claims to U.S. practice, to eliminate multiple dependencies, and to reduce the filing fee by rewriting some independent claims in dependent form. Support for new claim 24 may be found in original claim 26. Accordingly, applicants respectfully request entry of the replacement claims.

Attached hereto is a marked-up version of original claims 1-9 and 9-22 showing the changes made, captioned **"PLEASE DO NOT ENTER - Version with markings to show changes made."**

The filing fee has been calculated on the basis of the replacement claims. No additional fee is believed necessary in connection with this amendment. However, the fee transmittal submitted herewith authorizes payment of any additional fees.

Respectfully submitted,


Jeffrey M. Myers
Attorney for Applicant(s)
Reg. No. 41,213

Pfizer, Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-5061


18

PLEASE DO NOT ENTER - Version with markings to show changes made**Marked-up version of amended claims – PLEASE DO NOT ENTER**

Guide to claim amendments:


Insertions – underlinedDeletions – ~~strikethrough~~

1. (Amended) A compound of the formula:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 is C_{3-6} cycloalkyl optionally substituted by one or more fluorine atoms, or C_{1-6} alkyl optionally substituted by one or more fluorine atoms, or C_{3-6} cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms;

and

 R^2 is phenyl optionally substituted by one or more fluorine atoms:~~or a pharmaceutically acceptable salt or solvate thereof.~~2. (Amended) ~~A~~The compound as ~~claimed in~~of claim 1 of the formula:or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 ~~represents~~is either C_{3-6} cycloalkyl optionally substituted by one or more fluorine atoms, or C_{1-6} alkyl optionally substituted by one or more fluorine atoms, ~~or a pharmaceutically acceptable salt or solvate thereof.~~

3. (Amended) ~~A~~The compound as ~~claimed in~~of claim 1, wherein R^1 is either C_{4-6} cycloalkyl optionally substituted by one or two fluorine atoms, or C_{1-4} alkyl optionally substituted by from one to three fluorine atoms.

18

4. (Amended) ~~A~~The compound ~~as claimed in~~of claim 3, wherein R¹ is either cyclobutyl, cyclopentyl, 4,4-difluorocyclohexyl or 3,3,3-trifluoropropyl.

5. (Amended) ~~A~~The compound ~~as claimed in~~of claim 1, ~~3 or 4~~ wherein R² is phenyl optionally substituted by 1 or 2 fluorine atom(s).

6. (Amended) ~~A~~The compound ~~as claimed in~~of claim 5, wherein R² is phenyl or monofluorophenyl.

7. (Amended) ~~A~~The compound ~~as claimed in~~of claim 6, wherein R² is phenyl or 3-fluorophenyl.

8. (Amended) ~~A~~The compound ~~as claimed in~~of claim 1 which is selected from the group consisting of:

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-

azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl)cyclobutanecarboxamide;

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-

azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl)cyclopentanecarboxamide;

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-

azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl)-4,4,4-trifluorobutanamide;

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-

azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl)-4,4-difluorocyclohexanecarboxamide;

and

N-((1S)-3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-

azabicyclo[3.2.1]oct-8-yl]-1-(3-fluorophenyl)propyl)-4,4-

difluorocyclohexanecarboxamide;

or a pharmaceutically acceptable salt or solvate of any thereof.

9. (Amended) A pharmaceutical composition ~~including~~comprising a compound of the formula (I) ~~or a pharmaceutically acceptable salt or solvate thereof, as claimed in any preceding claim 1, together with~~ and one of a pharmaceutically acceptable excipient, a pharmaceutically acceptable diluent or a pharmaceutically acceptable carrier.

19. (Amended) A method of ~~treating~~ment of in a mammal ~~to treat a disorder in which the modulation of CCR5 receptors is implicated, including~~ treating which comprises administering to said mammal with an effective amount of a compound of the formula (I)

18

~~or with a pharmaceutically acceptable salt, solvate or composition thereof as claimed in any one of claims 1 to 8 and 9, respectively.~~

20. (Amended) A method of ~~treating~~ment of a mammal to treat HIV, a retroviral infection genetically related to HIV, AIDS, or an inflammatory disease, in a mammal, which comprises administering to ~~including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof as claimed in any one of claims 1 to 8 and 9, respectively.~~

21. (Amended) A method of ~~treating~~in a mammal, ment of a mammal to treat a respiratory disorder ~~including~~selected from adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis ~~or~~and chronic sinusitis, including treating which comprises administering to said mammal with an effective amount of a compound of the formula (I) ~~or with a pharmaceutically acceptable salt, solvate or composition thereof as claimed in any one of claims 1 to 8 and 9, respectively.~~

22. (Amended) A method of ~~treating~~in a mammal, ment of a mammal to treat an inflammatory bowel disease, ~~including Crohn's disease or ulcerative colitis~~, multiple sclerosis, rheumatoid arthritis, graft rejection, including a kidney or a lung allograft, endometriosis, type I diabetes, a renal disease, chronic pancreatitis, an inflammatory lung condition or chronic heart failure including treating which comprises administering to said mammal with an effective amount of a compound of the formula (I) ~~or with a pharmaceutically acceptable salt, solvate or composition thereof as claimed in any one of claims 1 to 8 and 9, respectively.~~

18